



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/648,136	08/26/2003	Kendall M. Mohler	2959-B	3243
22932	7590	08/08/2006	EXAMINER	
IMMUNEX CORPORATION LAW DEPARTMENT 1201 AMGEN COURT WEST SEATTLE, WA 98119			HADDAD, MAHER M	
			ART UNIT	PAPER NUMBER
			1644	

DATE MAILED: 08/08/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

SUPPLEMENTAL EXAMINER'S AMENDMENT

1. This supplemental Examiner's amendment is to correct a typographical error. Seronegative spondylarthropathies and inflammatory bowel diseases should be seronegative spondylarthropathy and inflammatory bowel disease, respectively.
2. An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to Applicant, an amendment may be filed as provided by 37 C.F.R. § 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the Issue Fee.
3. Authorization for this Examiner's Amendment was given in a telephone interview with Susan E. Lingenfelter on July 25, 2006.

In the Claims:


1. Claims 24-28 have been canceled.
2. In claim 1, the phrase "and further wherein the patient's condition is selected from the group consisting of psoriatic arthritis; arthritis nodosa; seronegative spondylarthropathies, and inflammatory bowel diseases" has been deleted.
3. In claim 1, the phrase "an autoimmune or chronic inflammatory condition" has been replaced with -- psoriatic arthritis, arthritis nodosa, seronegative spondylarthropathy or inflammatory bowel disease -- .
4. In claim 3, the word "condition" has been replaced with -- seronegative spondylarthropathy -
- .
5. In claim 4, the word "the condition is psoriatic arthritis" has been replaced with -- the psoriatic arthritis is treated -- .
6. In claim 5, the word "condition" has been replaced with -- inflammatory bowel disease -- .
7. In claim 6, the phrase ", IL-1 α , IL-1 β , or IL-4" has been deleted.
8. Claims 1-23 are allowable.
9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maher Haddad whose telephone number is (571) 272-0845. The examiner can normally be reached Monday through Friday from 7:30 am to 4:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are

Art Unit: 1644

unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841. The fax number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

July 25, 2006


Maher Haddad, Ph.D.
Primary Examiner
Technology Center 1600